GSK - VBI Vaccines boasts of new follow-up data for hepatitis B vaccine over GSK rival

VBI Vaccines (NASDAQ:VBIV) said that its 3-antigen hepatitis B (HBV) vaccine was more effective than GlaxoSmithKline's (GSK) Engerix-B, a single-antigen vaccine, based on phase 3, long-term follow-up data. VBI (VBIV) found that based on a follow-up analysis, participants who received the 3-antigen HBV vaccine had 5.5-fold higher mean anti-HBs titers and a higher seroprotection rate (SPR: 88.1% vs. 72.4%) compared to those given Engerix-B. The results, presented at the recent International Liver Congress 2022, were based on following patients 2.5 years after completing vaccination. VBI's (VBIV) brain cancer vaccine candidate recently received U.S. FDA Orphan Drug designation.

For further details see:

VBI Vaccines boasts of new follow-up data for hepatitis B vaccine over GSK rival